Impaired dopamine storage resulting from α-synuclein mutations may contribute to the pathogenesis of Parkinson's disease

Human Molecular Genetics

Volumn 11, Issue 20, 2002, Pages 2395-2407

  Lotharius, Julie ^a   Brundin, Patrik ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; DOPAMINE; FATTY ACID; NEUROTRANSMITTER; PHOSPHOLIPASE D;

AUTOSOMAL DOMINANT INHERITANCE; BINDING KINETICS; CELL LOSS; CONTROLLED STUDY; CORPUS STRIATUM; CYTOPLASM; DEGENERATIVE DISEASE; DOPAMINE METABOLISM; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; ENZYME REGULATION; GENE MUTATION; HUMAN; METABOLIC DISORDER; NERVE CELL LESION; NERVE CELL PLASTICITY; NEUROPATHOLOGY; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SUBSTANTIA NIGRA; SYNAPSE VESICLE; SYNAPTOSOME;

ALPHA-SYNUCLEIN; ANIMALS; CYTOSOL; DOPAMINE; FATTY ACIDS; HOMEOSTASIS; HUMANS; MUTATION; NERVE TISSUE PROTEINS; PARKINSON DISEASE; PHOSPHOLIPASE D; PROTEIN BINDING; SYNAPTIC VESICLES; SYNUCLEINS; TORPEDO;

DISCOPYGE OMMATA; TORPEDO;

EID: 0036797552     PISSN: 09646906     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (179)

1. de Rijk, M.C., Launer, L.J., Berger, K., Breteler, M.M., Dartigues, J.F., Baldereschi, M., Fratiglioni, L., Lobo, A., Martinez-Lage, J., Trenkwalder, C. et al. (2000) Prevalence of Parkinson's disease in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology, 54, S21-S23.
2. Hirsch, E., Graybiel, A.M. and Agid, Y.A. (1988) Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature, 334, 345-348.
3. Fearnley, J.M. and Lees, AJ (1991) Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain, 114, 2283-2301.
4. Pakkenberg, B., Moller, A., Gundersen, H.J., Mouritzen Dam, A. and Pakkenberg, H. (1991) The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson's disease estimated with an unbiased stereological method. J. Neurol. Neurosurg. Psychiatry, 54, 30-33.
5. Hornykiewicz, O. (1998) Biochemical aspects of Parkinson's disease. Neurology, 51, S2-S9.
6. Lewy, F.H. (1912) In Paralysis Agitans. Lewandowski, M. and Abelsdorff, G (eds), Handbuch der Neurologie. Springer-Verlag, Berlin, Ed. III, S. 920-933.
7. Spillantini, M.G., Schmidt, M.L., Lee, V.M., Trojanowski, J.Q., Jakes, R. and Goedert, M. (1997) α-Synuclein in Lewy bodies. Nature, 388, 839-840.
8. Jellinger, K.A. (1999) Post mortem studies in Parkinson's disease - Is it possible to detect brain areas for specific symptoms? J. Neural Transm. Suppl., 56, 1-29.
9. Halliwell, B. (1992) Reactive oxygen species and the central nervous system. J. Neurochem., 59, 1609-1623.
10. Zhang, Y., Dawson, V.L. and Dawson, T.M. (2000) Oxidative stress and genetics in the pathogenesis of Parkinson's disease, Neurobiol. Dis., 7, 240-250.
11. Graham, D.G. (1978) Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinines. Mol. Pharmacol., 14, 633-643.
12. Maker, H.S., Weiss, C., Silides, D.J. and Cohen, G. (1981) Coupling of dopamine oxidation (monoamine oxidase activity) to glutathione oxidation via the generation of hydrogen peroxide in rat brain homogenates. J. Neurochem., 36, 589-593.
13. Ben-Shachar, D., Zuk, R. and Glinka, Y. (1995) Dopamine neurotoxicity: inhibition of mitochondrial respiration. J. Neurochem., 64, 718-723.
14. Glinka, Y.Y. and Youdim, M.B. (1995) Inhibition of mitochondrial complexes I and IV by 6-hydroxydopamine. Ear. J. Pharmacol., 292, 329-332.
15. Suzuki, K., Mizuno, Y., Yamauchi, Y., Nagatsu, T. and Mitsuo, Y. (1992) Selective inhibition of complex I by N-methylisoquinolinium ion and N-methyl-1,2,3,4-tetrahydroisoquinoline in isolated mitochondria prepared from mouse brain. J. Neurol. Sci., 109, 219-223.
16. Reichmann, H. and Janetzky, B. (2000) Mitochondrial dysfunction - a pathogenetic factor in Parkinson's disease. J. Neurol., 247(Suppl. 2), II63-II68.
17. Hirsch, E.C. (1993) Does oxidative stress participate in nerve cell death in Parkinson's disease? Eur. Neurol., 33, 52-59.
18. Jenner, P. (1998) Oxidative mechanisms in nigral cell death in Parkinson's disease. Mov. Disord., 13, 24-34.
19. Dexter, D.T, Carter, C.J., Wells, F.R., Javoy-Agid, F., Agid, Y., Lees, A., Jenner, P. and Marsden, C.D. (1989) Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J. Neurochem., 52, 381-389.
20. Sofic, E., Riederer, R, Heinsen, H., Beckmann, H., Reynolds, G.P., Hebenstreit, G. and Youdim, M.B. (1988) Increased iron(III) and total iron content in post mortem substantia nigra of parkinsonian brain. J. Neural. Transm., 74, 199-205.
21. Saggu, H., Cooksey, J., Dexter, D., Wells, F.R., Lees, A., Jenner, P. and Marsden, C.D. (1989) A selective increase in particulate superoxide dismutase activity in parkinsonian substantia nigra. J. Neurochem., 53, 692-697.
22. Sofic, E., Lange, K.W, Jellinger, K. and Riederer, P. (1992) Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci. Lett., 142, 128-130.
23. Yoritaka, A., Hattori, N., Uchida, K., Tanaka, M., Stadtman, E.R. and Mizuno, Y. (1996) Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc. Natl Acad. Sci. USA, 93, 2696-2701.
24. Alam, Z.I., Daniel, S.E., Lees, A.J., Marsden, D.C., Jenner, P. and Halliwell, B. (1997) A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. J. Neurochem., 69, 1326-1329.
25. Floor, E. and Wetzel, M.G. (1998) Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay, J. Neurochem., 70, 268-275.
26. Alam, Z.I., Jenner, A., Daniel, S.E., Lees, A.J., Cairns, N., Marsden, C.D., Jenner, P. and Halliwell, B. (1997) Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J. Neurochem., 69, 1196-1203.
27. Maruyama, W., Abe, T., Tohgi, H., Dostert, P. and Naoi, M. (1996) A dopaminergic neurotoxin, (R)-N-methylsalsolinol, increases in parkinsonian cerebrospinal fluid. Ann. Neurol., 40, 119-122.
28. Zigmond, M.J., Abercrombie, E.D., Berger, T.W, Grace, A.A. and Stricker, E.M. (1990) Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci., 13, 290-296.
29. Dexter, D.T., Nanayakkara, I., Goss-Sampson, M.A., Muller, D.P., Harding, A.E., Marsden, C.D. and Jenner, P. (1994) Nigral dopaminergic cell loss in vitamin E deficient rats. Neuroreport, 5, 1773-1776.
30. Sulzer, D. and Rayport, S. (1990) Amphetamine and other psychostimulants reduce pH gradients in midbrain dopaminergic neurons and chromaffin granules: a mechanism of action. Neuron, 5, 797-808.
31. Sulzer, D., Chen, T.K., Lau, Y.Y., Kristensen, H., Rayport, S. and Ewing, A. (1995) Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J. Neurosci., 15, 4102-4108.
32. Jones, S.R., Gainetdinov, R.R., Wightman, R.M. and Caron, M.G. (1998) Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter. J. Neurosci., 18, 1979-1986.
33. Sulzer, D., Maidment, N.T. and Rayport, S. (1993) Amphetamine and other weak bases act to promote reverse transport of dopamine in ventral midbrain neurons. J. Neurochem., 60, 527-535.
34. Cubells, J.F., Rayport, S., Rajendran, G. and Sulzer, D. (1994) Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress. J. Neurosci., 14, 2260-2271.
35. Lotharius, J. and O'Malley, K.L. (2001) Role of mitochondrial dysfunction and dopamine-dependent oxidative stress in amphetamine-induced toxicity. Ann. Neurol., 49, 79-89.
36. LaVoie, M.J. and Hastings, T.G. (1999) Dopamine quinone formulation and protein modification associated with the striatol neurotoxicity of methamphetamine: evidence against a role of extracellular dopamine. J. Neurosci., 19, 1484-1491.
37. Ricaurte, G.A., Seiden, L.S. and Schuster, C.R. (1984) Further evidence that amphetamines produce long-lasting dopamine neurochemical deficits by destroying dopamine nerve fibers. Brain Res., 303, 359-364.
38. Sonsalla, RK., Jochnowitz, N.D., Zeevalk, G.D., Oostveen, J.A. and Hall, E.D. (1996) Treatment of mice with methamphetamine produces cell loss in the substantia nigra. Brain Res., 738, 172-175.
39. Cadet, J.L., Ali, S. and Epstein, C. (1994) Involvement of oxygen-based radicals in methamphetamine-induced neurotoxicity: evidence from the use of CuZnSOD transgenic mice. Ann. NY Acad. Sci., 738, 388-391.
40. De Vito, M.J. and Wagner, G.C. (1989) Methamphetamine-induced neuronal damage: a possible role for free radicals. Neuropharmacology, 28, 1145-1150.
41. Schmidt, C.J., Ritter, J.K., Sonsalla, P.K., Hanson, G.R. and Gibb, J.W. (1985) Role of dopamine in the neurotoxic effects of methamphetamine. J. Pharmacol. Exp. Ther, 233, 539-544.
42. Wagner, G.C., Jarvis, M.F. and Carelli, R.M. (1985) Ascorbic acid reduces the dopamine depletion induced by MPTP. Neuropharmacology, 24, 1261-1262.
43. +) in isolated mitochondria from mouse brains. Neurosci. Lett., 81, 204-208.
44. Nicklas, W.J., Vyas, I. and Heikkila, R.E. (1985) Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenylpyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci., 36, 2503-2508.
45. Ramsay, R.R., Salach, J.I., Dadgar, J. and Singer, T.P. (1986) Inhibition of mitochondrial NADH dehydrogenase by pyridine derivatives and its possible relation to experimental and idiopathic parkinsonism. Biochem. Biophys. Res. Commun., 135, 269-275.
46. Daniels, A.J. and Reinhard, J.F., Jr (1988) Energy-driven uptake of the neurotoxin 1-methyl-4-phenylpyridinium into chromaffin granules via the catecholamine transporter. J. Biol. Chem., 263, 5034-5036.
47. 3H]1-methyl-4-phenyl-2,3-dihydropyridinium ion to mouse striatal membranes: putative vesicular location. Eur. J. Pharmacol., 202, 293-294.
48. + uptake into synaptic dopamine vesicles: possible involvement in MPTP neurotoxicity. Br J. Pharmacol., 109, 411-414.
49. Reinhard, J.F., Jr, Diliberto, E.J., Jr, Viveros, O.H. and Daniels, A.J. (1987) Subcellular compartmentalization of 1-methyl-4-phenylpyridinium with catecholamines in adrenal medullary chromaffin vesicles may explain the lack of toxicity to adrenal chromaffin cells. Proc. Natl Acad. Sci. USA, 84, 8160-8164.
50. Lotharius, J. and O'Malley, K.L. (2000) The parkinsonism-inducing drug 1-methyl-4-phenylpyridinium triggers intracellular dopamine oxidation. A novel mechanism of toxicity. J. Biol. Chem., 275, 38581-38588.
51. Gasser, T. (2001) Genetics of Parkinson's disease. J. Neurol., 248, 833-840.
52. Polymeropoulos, M.H., Lavedan, C., Leroy, E., Ide, S.E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R. et al. (1997) Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science, 276, 2045-2047.
53. Kruger, R., Kuhn, W, Muller, T., Woitalla, D., Graeber, M., Kesel, S., Przuntek, H., Epplen, J.T., Schols, L. and Riess, O. (1998) Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease. Nat. Genet., 18, 106-108.
54. Scott, W.K., Yamaoka, L.H., Stajich, J.M., Scott, B.L., Vance, J.M., Roses, A.D., Pericak-Vance, M.A., Watts, R.L., Nance, M., Hubble, J. et al. (1999) The α-synuclein gene is not a major risk factor in familial Parkinson disease. Neurogenetics, 2, 191-192.
55. Farrer, M., Maraganore, D.M., Lockhart, R, Singleton, A., Lesnick, T.G., de Andrade, M., West, A., de Silva, R., Hardy, J. and Hernandez, D. (2001) α-synuclein gene haplotypes are associated with Parkinson's disease. Hum. Mol. Genet., 10, 1847-1851.
56. Bostantjopoulou, S., Katsarou, Z., Papadimitriou, A., Veletza, V, Hatzigeorgiou, G. and Lees, A. (2001) Clinical features of parkinsonian patients with the α-synuclein (G209A) mutation. Mov. Disord., 16, 1007-1013.
57. Spira, P.J., Sharpe, D.M., Halliday, G., Cavanagh, J. and Nicholson, G.A. (2001) Clinical and pathological features of a Parkinsonian syndrome in a family with an Ala53Thr α-synuclein mutation. Ann. Neurol., 49, 313-319.
58. George, J.M. (2002) The synucleins. Genome Biol., 3, 1-6.
59. Ueda, K., Fukushima, H., Masliah, E., Xia, Y., Iwai, A., Yoshimoto, M., Otero, D.A., Kondo, J., Ihara, Y. and Saitoh, T. (1993) Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc. Natl Acad. Sci. USA, 90, 11282-11286.
60. Lucking, C.B. and Brice, A. (2000) α-Synuclein and Parkinson's disease. Cell. Mol. Life Sci., 57, 1894-1908.
61. Ellis, C.E., Schwartzberg, P.L., Grider, T.L., Fink, D.W. and Nussbaum, R.L. (2001) α-Synuclein is phosphorylated by members of the Src family of protein-tyrosine kinases. J. Biol. Chem., 276, 3879-3884.
62. Nakamura, T, Yamashita, H., Nagano, Y, Takahashi, T., Avraham, S., Avraham, H., Matsumoto, M. and Nakamura, S. (2002) Activation of Pyk2/RAFTK induces tyrosine phosphorylation of α-synuclein via Src-family kinases. FEBS Lett., 521, 190-194.
63. Negro, A., Brunati, A.M., Donella-Deana, A., Massimino, M.L. and Pinna, L.A. (2002) Multiple phosphorylation of α-synuclein by protein tyrosine kinase Syk prevents eosin-induced aggregation. FASEB J., 16, 210-212.
64. Okochi, M., Walter, J., Koyama, A., Nakajo, S., Baba, M., Iwatsubo, T., Meijer, L., Kahle, P.J. and Haass, C. (2000) Constitutive phosphorylation of the Parkinson's disease associated α-synuclein. J. Biol. Chem., 275, 390-397.
65. Pronin, A.N., Morris, A.J., Surguchov, A. and Benovic, J.L. (2000) Synucleins are a novel class of substrates for G protein-coupled receptor kinases. J. Biol. Chem., 275, 26515-26522.
66. Davidson, W.S., Jonas, A., Clayton, D.F. and George, J.M. (1998) Stabilization of α-synuclein secondary structure upon binding to synthetic membranes. J. Biol. Chem., 273, 9443-9449.
67. Weinreb, P.H., Zhen, W, Poon, A.W, Conway, K.A. and Lansbury, P.T., Jr (1996) NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry, 35, 13709-13715.
68. Conway, K.A., Harper, J.D. and Lansbury, P.T. (1998) Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease. Nat. Med., 4, 1318-1320.
69. Giasson, B.I., Uryu, K., Trojanowski, J.Q. and Lee, V.M. (1999) Mutant and wild type human α-synucleins assemble into elongated filaments with distinct morphologies in vitro. J. Biol. Chem., 274, 7619-7622.
70. Harper, J.D., Lieber, C.M. and Lansbury, P.T., Jr (1997) Atomic force microscopic imaging of seeded fibril formation and fibril branching by the Alzheimer's disease amyloid-β protein. Chem. Biol., 4, 951-959.
71. Harper, J.D., Wong, S.S., Lieber, C.M. and Lansbury, P.T., Jr (1999) Assembly of A β amyloid protofibrils: an in vitro model for a possible early event in Alzheimer's disease. Biochemistry, 38, 8972-8980.
72. Conway, K.A., Lee, S.J., Rochet, J.C., Ding, T.T., Harper, J.D., Williamson, R.E. and Lansbury, P.T. (2000) Accelerated oligomerization by Parkinson's disease linked α-synuclein mutants. Ann. NY Acad. Sci., 920, 42-45.
73. Conway, K.A., Rochet, J.C., Bieganski, R.M. and Lansbury, P.T., Jr (2001) Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-α-synuclein adduct. Science, 294, 1346-1349.
74. Fujiwara, H., Hasegawa, M., Dohmae, N., Kawashima, A.,,Masliah, E., Goldberg, M.S., Shen, J., Takio, K. and Iwatsubo, T. (2002) α-Synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol., 4, 160-164.
75. Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y. and Shimizu, N. (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature, 392, 605-608.
76. Shimura, H., Hattori, N., Kubo, S., Mizuno, Y., Asakawa, S., Minoshima, S., Shimizu, N., Iwai, K., Chiba, T, Tanaka, K. et al. (2000) Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet., 25, 302-305.
77. Shimura, H., Schlossmacher, M.G., Hattori, N., Frosch, M.P., Trockenbacher, A., Schneider, R., Mizuno, Y, Kosik, K.S. and Selkoe, D.J. (2001) Ubiquitination of a new form of α-synuclein by parkin from human brain: implications for Parkinson's disease. Science, 293, 263-269.
78. Chung, K.K., Zhang, Y., Lim, K.L., Tanaka, Y., Huang, H., Gao, J., Ross, C.A., Dawson, V.L. and Dawson, T.M. (2001) Parkin ubiquitinates the α-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. Nat. Med., 7, 1144-1150.
79. Hashimoto, M., Hsu, L.J., Xia, Y., Takeda, A., Sisk, A., Sundsmo, M. and Masliah, E. (1999) Oxidative stress induces amyloid-like aggregate formation of NACP/α-synuclein in vitro. Neuroreport, 10, 717-721.
80. Paxinou, E., Chen, Q., Weisse, M., Giasson, B.I., Norris, E.H., Rueter, S.M., Trojanowski, J.Q., Lee, V.M. and Ischiropoulos, H. (2001) Induction of α-synuclein aggregation by intracellular nitrative insult. J. Neurosci., 21, 8053-8061.
81. Iwai, A., Masliah, E., Yoshimoto, M., Ge, N., Flanagan, L., de Silva, H.A., Kittel, A. and Saitoh, T. (1995) The precursor protein of non-A β component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron, 14, 467-475.
82. Kruger, R., Muller, T. and Riess, O. (2000) Involvement of α-synuclein in Parkinson's disease and other neurodegenerative disorders. J. Neural Transm., 107, 31-40.
83. Maroteaux, L., Campanelli, J.T. and Scheller, R.H. (1988) Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J. Neurosci., 8, 2804-2815.
84. Irizarry, M.C., Kim, T.W, McNamara, M., Tanzi, R.E., George, J.M., Clayton, D.F. and Hyman, B.T. (1996) Characterization of the precursor protein of the non-A β component of senile plaques (NACP) in the human central nervous system. J. Neuropathol. Exp. Neurol., 55, 889-895.
85. Bayer, T.A., Jakala, P, Hartmann, T., Egensperger, R., Buslei, R., Falkai, P. and Beyreuther, K. (1999) Neural expression profile of α-synuclein in developing human cortex. Neuroreport, 10, 2799-2803.
86. Galvin, J.E., Schuck, T.M., Lee, VM. and Trojanowski, J.Q. (2001) Differential expression and distribution of α-, β-, and γ-synuclein in the developing human substantia nigra. Exp. Neurol., 168, 347-355.
87. Hsu, L.J., Mallory, M., Xia, Y., Veinbergs, L, Hashimoto, M., Yoshimoto, M., Thal, L.J., Saitoh, T. and Masliah, E. (1998) Expression pattern of synucleins (non-A β component of Alzheimer's disease amyloid precursor protein/α-synuclein) during murine brain development. J. Neurochem., 71, 338-344.
88. Shibayama-Imazu, T., Okahashi, I., Omata, K., Nakajo, S., Ochiai, H., Nakai, Y., Hama, T., Nakamura, Y. and Nakaya, K. (1993) Cell and tissue distribution and developmental change of neuron specific 14 kDa protein (phosphoneuroprotein 14). Brain Res., 622, 17-25.
89. Abeliovich, A., Schmitz, Y., Farinas, I, Choi-Lundberg, D., Ho, W.H., Castillo, P.E., Shinsky, N., Verdugo, J.M., Armanini, M., Ryan, A. et al. (2000) Mice lacking α-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron, 25, 239-252.
90. Cabin, D., Murphy, D., Shimazu, K., Cole, N.B., Gottschalk, W, McIlwain, K.C., Orrison, B., Chen, A., Ellis, C.E., Paylor, R. et al. (2002) Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking α-synuclein. J. Neurosci., in press.
91. Masliah, E., Rockenstein, E., Veinbergs, L, Mallory, M., Hashimoto, M., Takeda, A., Sagara, Y., Sisk, A. and Mucke, L. (2000) Dopaminergic loss and inclusion body formation in α-synuclein mice: implications for neurodegenerative disorders. Science, 287, 1265-1269.
92. van der Putten, H., Wiederhold, K.H., Probst, A., Barbieri, S., Mistl, C., Danner, S., Kauffmann, S., Hofele, K., Spooren, W.P., Ruegg, M.A. et al. (2000) Neuropathology in mice expressing human α-synuclein. J. Neurosci., 20, 6021-6029.
93. Giasson, B.I., Duda, J.E., Quinn, S.M., Zhang, B., Trojanowski, J.Q. and Lee, VM. (2002) Neuronal α-synucleinopathy with severe movement disorder in mice expressing A53T human α-synuclein. Neuron, 34, 521-533.
94. Lee, M.K., Stirling, W, Xu, Y., Xu, X., Qui, D., Mandir, A.S., Dawson, T.M., Copeland, N.G., Jenkins, N.A. and Price, D.L. (2002) Human α-synuclein-harboring familial Parkinson's disease-linked Ala-53→Thr mutation causes neurodegenerative disease with α-synuclein aggregation in transgenic mice. Proc. Natl Acad. Sci. USA, 99, 8968-8973.
95. Matsuoka, Y., Vila, M., Lincoln, S., McCormack, A., Picciano, M., LaFrancois, J., Yu, X., Dickson, D., Langston, W.J., McGowan, E. et al. (2001) Lack of nigral pathology in transgenic mice expressing human α-synuclein driven by the tyrosine hydroxylase promoter. Neurobiol. Dis., 8, 535-539.
96. Rathke-Hartlieb, S., Kahle, P.J., Neumann, M., Ozmen, L., Haid, S., Okochi, M., Haass, C. and Schulz, J.B. (2001) Sensitivity to MPTP is not increased in Parkinson's disease-associated mutant α-synuclein transgenic mice. J. Neurochem., 77, 1181-1184.
97. Richfield, E.K., Thiruchelvam, M.J., Cory-Slechta, D.A., Wuertzer, C., Gainetdinov, R.R., Caron, M.G., Di Monte, D.A. and Federoff, H.J. (2002) Behavioral and neurochemical effects of wild-type and mutated human α-synuclein in transgenic mice. Exp. Neurol., 175, 35-48.
98. Harata, N., Pyle, J.L., Aravanis, A.M., Mozhayeva, M., Kavalali, E.T. and Tsien, R.W. (2001) Limited numbers of recycling vesicles in small CNS nerve terminals: implications for neural signaling and vesicular cycling. Trends Neurosci., 24, 637-643.
99. Sudhof, T.C. (2000) The synaptic vesicle cycle revisited. Neuron, 28, 317-320.
100. McNiven, M.A., Kim, L., Krueger, E.W, Orth, J.D., Cao, H. and Wong, T.W. (2000) Regulated interactions between dynamin and the actin-binding protein cortactin modulate cell shape. J. Cell Biol., 151, 187-198.
101. Heuser, J.E. and Reese, T.S. (1973) Evidence for recycling of synaptic vesicle membrane during transmitter release at the frog neuromuscular junction. J. Cell Biol., 57, 315-344.
102. Murthy, V.N. and Stevens, C.F. (1998) Synaptic vesicles retain their identity through the endocytic cycle. Nature, 392, 497-501.
103. Sudhof, T.C. (1995) The synaptic vesicle cycle: a cascade of protein-protein interactions. Nature, 375, 645-653.
104. Takei, K., Mundigl, O., Daniell, L. and De Camilli, P. (1996) The synaptic vesicle cycle: a single vesicle budding step involving clathrin and dynamin. J. Cell Biol., 133, 1237-1250.
105. Ceccarelli, B., Hurlbut, W.P. and Mauro, A. (1973) Turnover of transmitter and synaptic vesicles at the frog neuromuscular junction. J. Cell Biol., 57, 499-524.
106. Valtorta, F., Meldolesi, J. and Fesce, R. (2001) Synaptic vesicles: Is kissing a matter of competence? Trends Cell Biol., 11, 324-328.
107. Verstreken, P, Kjaerulff, O., Lloyd, T.E., Atkinson, R., Zhou, Y., Meinertzhagen, I.A. and Bellen, H.J. (2002) Endophilin mutations block clathrin-mediated endocytosis but not neurotransmitter release. Cell, 109, 101-112.
108. Ryan, T.A., Li, L., Chin, L.S., Greengard, P. and Smith, S.J. (1996) Synaptic vesicle recycling in synapsin I knock-out mice. J. Cell Biol., 134, 1219-1227.
109. Jensen, P.H., Nielsen, M.S., Jakes, R., Dotti, C.G. and Goedert, M. (1998) Binding of α-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation. J. Biol. Chem., 273, 26292-26294.
110. Kahle, P.J., Neumann, M., Ozmen, L., Muller, V., Jacobsen, H., Schindzielorz, A., Okochi, M., Leimer, U., van Der Putten, H., Probst, A. et al. (2000) Subcellular localization of wild-type and Parkinson's disease-associated mutant α-synuclein in human and transgenic mouse brain. J. Neurosci., 20, 6365-6373.
111. McLean, P.J., Kawamata, H., Ribich, S. and Hyman, B.T. (2000) Membrane association and protein conformation of α-synuclein in intact neurons. Effect of Parkinson's disease-linked mutations. J Biol. Chem., 275, 8812-8816.
112. Sharon, R., Goldberg, M.S., Bar-Josef, I., Betensky, R.A., Shon, J. and Selkoc, D.J. (2001) α-Synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and shows homology to the fatty acid-binding proteins. Proc. Natl Acad. Sci. USA, 98, 9110-9115.
113. Clayton, D.F. and George, J.M. (1999) Synucleins in synaptic plasticity and neurodegenerative disorders. J. Neurosci. Res., 58, 120-129.
114. Nakajo, S., Shioda, S., Nakai, Y. and Nakaya, K. (1994) Localization of phosphoneuroprotein 14 (PNP 14) and its mRNA expression in rat brain determined by immunocytochemistry and in situ hybridization. Brain Res. Mol. Brain Res., 27, 81-86.
115. George, J.M., Jin, H., Woods, WS. and Clayton, D.F. (1995) Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron, 15, 361-372.
116. Sudhof, T.C., Lottspeich, F., Greengard, P, Mehl, E. and Jahn, R. (1987) A synaptic vesicle protein with a novel cytoplasmic domain and four transmembrane regions. Science, 238, 1142-1144.
117. Narayanan, V. and Scarlata, S. (2001) Membrane binding and self-association of α-synucleins. Biochemistry, 40, 9927-9934.
118. Michaelson, D.M., Barkai, G. and Barenholz, Y. (1983) Asymmetry of lipid organization in cholinergic synaptic vesicle membranes. Biochem. J., 211, 155-162.
119. Jo, E., Fuller, N., Rand, R.P., St George-Hyslop, P. and Fraser, P.E. (2002) Defective membrane interactions of familial Parkinson's disease mutant A30P α-synuclein. J. Mol. Biol., 315, 799-807.
120. McLean, P.J., Ribich, S. and Hyman, B.T. (2000) Subcellular localization of α-synuclein in primary neuronal cultures: effect of missense mutations. J. Neural Transm., 58(Suppl), 53-63.
121. Perrin, R.J., Woods, W.S., Clayton, D.F. and George, J.M. (2000) Interaction of human α-synuclein and Parkinson's disease variants with phospholipids. Structural analysis using site-directed mutagenesis. J. Biol. Chem., 275, 34393-34398.
122. Jo, E., McLaurin, J., Yip, C.M., St George-Hyslop, P. and Fraser, P.E. (2000) α-Synuclein membrane interactions and lipid specificity. J. Biol. Chem., 275, 34328-34334.
123. Volles, M.J., Lee, S.J., Rochet, J.C., Shtilerman, M.D., Ding, T.T., Kessler, J.C. and Lansbury, P.T., Jr (2001) Vesicle permeabilization by protofibrillar α-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry, 40, 7812-7819.
124. Volles, M.J. and Lansbury, P.T., Jr (2002) Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. Biochemistry, 41, 4595-4602.
125. Ahn, B.H., Rhim, H., Kim, S.Y., Sung, Y.M., Lee, M.Y., Choi, J.Y., Wolozin, B., Chang, J.S., Lee, Y.H., Kwon, T.K. et al. (2002) α-Synuclein interacts with phospholipase D isozymes and inhibits pervanadate induced phospholipase D activation in human embryonic kidney 293 cells. J. Biol. Chem., 30, 30.
126. Jenco, J.M., Rawlingson, A., Daniels, B. and Morris, A.J. (1998) Regulation of phospholipase D2: selective inhibition of mammalian phospholipase D isoenzymes by α- and β-synucleins. Biochemistry, 37, 4901-4909.
127. Exton, J.H. (2002) Phospholipase D - structure, regulation and function. Rev. Physiol. Biochem. Pharmacol., 144, 1-94.
128. Jones, D., Morgan, C. and Cockcroft, S. (1999) Phospholipase D and membrane traffic. Potential roles in regulated exocytosis, membrane delivery and vesicle budding. Biochim. Biophys. Acta, 1439, 229-244.
129. Ktistakis, N.T., Brown, H.A., Sternweis, P.C. and Roth, M.G. (1995) Phospholipase D is present on Golgi-enriched membranes and its activation by ADP ribosylation factor is sensitive to brefeldin A. Proc. Natl Acad. Sci. USA, 92, 4952-4956.
130. Whatmore, J., Morgan, C.P., Cunningham, E., Collison, K.S., Willison, K.R. and Cockcroft, S. (1996) ADP-ribosylation factor 1-regulated phospholipase D activity is localized at the plasma membrane and intracellular organelles in HL60 cells. Biochem. J., 320, 785-794.
131. Choi, W.S., Kim, Y.M., Combs, C., Frohman, M.A. and Beaven, M.A. (2002) Phospholipases D1 and D2 regulate different phases of exocytosis in mast cells. J. Immunol., 168, 5682-5689.
132. Colley, W.C., Sung, T.C., Roll, R., Jenco, J., Hammond, S.M., Altshuller, Y., Bar-Sagi, D., Morris, A.J. and Frohman, M.A. (1997) Phospholipase D2, a distinct phospholipase D isoform with novel regulatory properties that provokes cytoskeletal reorganization. Curr. Biol., 7, 191-201.
133. Lopez, I., Arnold, R.S. and Lambeth, J.D. (1998) Cloning and initial characterization of a human phospholipase D2 (hPLD2). ADP-ribosylation factor regulates hPLD2. J. Biol. Chem., 273, 12846-12852.
134. Blumstein, J., Faundez, V, Nakatsu, F., Saito, T., Ohno, H. and Kelly, R.B. (2001) The neuronal form of adaptor protein-3 is required for synaptic vesicle formation from endosomes. J. Neurosci., 21, 8034-8042.
135. Faundez, V, Horng, J.T. and Kelly, R.B. (1998) A function for the AP3 coat complex in synaptic vesicle formation from endosomes. Cell, 93, 423-432.
136. Lee, C., Kang, H.S., Chung, J.K., Sekiya, E, Kim, J.R., Han, J.S., Kim, S.R., Bae, Y.S., Morris, A.J. and Rhee, S.G. (1997) Inhibition of phospholipase D by clathrin assembly protein 3 (AP3). J. Biol. Chem., 272, 15986-15992.
137. Lukowski, S., Lecomte, M.C., Mira, J.P., Marin, R, Gautero, H., Russo-Marie, F. and Geny, B. (1996) Inhibition of phospholipase D activity by fodrin. An active role for the cytoskeleton. J. Biol. Chem., 271, 24164-24171.
138. Chung, J.K., Sekiya, F., Kang, H.S., Lee, C., Han, J.S., Kim, S.R., Bae, Y.S., Morris, A.J. and Rhee, S.G. (1997) Synaptojanin inhibition of phospholipase D activity by hydrolysis of phosphatidylinositol 4,5-bisphosphate. J. Biol. Chem., 272, 15980-15985.
139. Cremona, O., Di Paolo, G., Wenk, M.R., Luthi, A., Kim, W.T., Takei, K., Daniell, L., Nemoto, Y., Shears, S.B., Flavell, R.A. et al. (1999) Essential role of phosphoinositide metabolism in synaptic vesicle recycling. Cell, 99, 179-188.
140. Harris, T.W, Hartwieg, E., Horvitz, H.R. and Jorgensen, E.M. (2000) Mutations in synaptojanin disrupt synaptic vesicle recycling. J. Cell Biol., 150, 589-600.
141. Lee, C., Kim, S.R., Chung, J.K., Frohman, M.A., Kilimann, M.W. and Rhee, S.G. (2000) Inhibition of phospholipase D by amphiphysins. J. Biol. Chem., 275, 18751-18758.
142. Cockcroft, S. (2001) Signalling roles of mammalian phospholipase D1 and D2. Cell. Mol. Life Sci., 58, 1674-1687.
143. Humeau, Y., Vitale, N., Chasserot-Golaz, S., Dupont, J.L., Du, G., Frohman, M.A., Bader, M.F. and Poulain, B. (2001) A role for phospholipase D1 in neurotransmitter release. Proc. Natl Acad. Sci. USA, 98, 15300-15305.
144. Liscovitch, M., Czarny, M., Fiucci, G. and Tang, X. (2000) Phospholipase D: molecular and cell biology of a novel gene family. Biochem. J., 345, 401-415.
145. West, M.A., Bright, N.A. and Robinson, M.S. (1997) The role of ADP-ribosylation factor and phospholipase D in adaptor recruitment. J. Cell Biol., 138, 1239-1254.
146. Ktistakis, N.T, Brown, H.A., Waters, M.G., Sternweis, P.C. and Roth, M.G. (1996) Evidence that phospholipase D mediates ADP ribosylation factor-dependent formation of Golgi coated vesicles. J. Cell Biol., 134, 295-306.
147. Chen, YG., Siddhanta, A., Austin, C.D., Hammond, S.M., Sung, TC., Frohman, M.A., Morris, A.J. and Shields, D. (1997) Phospholipase D stimulates release of nascent secretory vesicles from the trans-Golgi network. J. Cell Biol., 138, 495-504.
148. Huttner, W.B. and Schmidt, A. (2000) Lipids, lipid modification and lipid-protein interaction in membrane budding and fission - insights from the roles of endophilin A1 and synaptophysin in synaptic vesicle endocytosis. Curr. Opin. Neurobiol., 10, 543-551.
149. Iacovelli, L., Sallese, M., Mariggio, S. and de Blasi, A. (1999) Regulation of G-protein-coupled receptor kinase subtypes by calcium sensor proteins. FASEB J., 13, 1-8.
150. Sallese, M., Iacovelli, L., Cumashi, A., Capobianco, L., Cuomo, L. and De Blasi, A. (2000) Regulation of G protein-coupled receptor kinase subtypes by calcium sensor proteins. Biochim. Biophys. Acta, 1498, 112-121.
151. Greengard, P, Valtorta, E, Czernik, A.J. and Benfenati, F. (1993) Synaptic vesicle phosphoproteins and regulation of synaptic function. Science, 259, 780-785.
152. Murphy, D.D., Rueter, S.M., Trojanowski, J.Q. and Lee, V.M. (2000) Synucleins are developmentally expressed, and α-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J. Neurosci., 20, 3214-3220.
153. 2+-dependent formation of a dynamin-synaptophysin complex: potential role in synaptic vesicle endocytosis. J. Biol. Chem., 277, 9010-9015.
154. Clayton, D.F. and George, J.M. (1998) The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. Trends Neurosci., 21, 249-254.
155. Blanco-Vaca, F, Escola-Gil, J.C., Martin-Campos, J.M. and Julve, J. (2001) Role of apoA-II in lipid metabolism and atherosclerosis: advances in the study of an enigmatic protein. J. Lipid Res., 42, 1727-1739.
156. Morrisett, J.D., Jackson, R.L. and Gotto, A.M., Jr (1977) Lipid-protein interactions in the plasma lipoproteins. Biochim. Biophys. Acta, 472, 93-133.
157. Hatters, D.M. and Howlett, G.J. (2002) The structural basis for amyloid formation by plasma apolipoproteins: a review. Eur. Biophys. J., 31, 2-8.
158. Wisniewski, T., Golabek, A.A., Kida, E., Wisniewski, K.E. and Frangione, B. (1995) Conformational mimicry in Alzheimer's disease. Role of apolipoproteins in amyloidogenesis. Am. J. Pathol., 147, 238-244.
159. Storch, J. and Thumser, A.E. (2000) The fatty acid transport function of fatty acid-binding proteins. Biochim. Biophys. Acta, 1486, 28-44.
160. Breckenridge, W.C., Gombos, G. and Morgan, I.G. (1972) The lipid composition of adult rat brain synaptosomal plasma membranes. Biochim. Biophys. Acta, 266, 695-707.
161. Westhead, E.W. (1987) Lipid composition and orientation in secretory vesicles. Ann. NY Acad. Sci., 493, 92-100.
162. Schmidt, A., Wolde, M., Thiele, C., Fest, W, Kratzin, H., Podtelejnikov, A.V., Witke, W., Huttner, W.B. and Soling, H.D. (1999) Endophilin I mediates synaptic vesicle formation by transfer of arachidonate to lysophosphatidic acid. Nature, 401, 133-141.
163. Hertzel, A.V. and Bernlohr, D.A. (2000) The mammalian fatty acid-binding protein multigene family: molecular and genetic insights into function. Trends Endocrinol. Metab., 11, 175-180.
164. Conway, K.A., Harper, J.D. and Lansbury, P.T., Jr (2000) Fibrils formed in vitro from α-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry, 39, 2552-2563.
165. El-Agnaf, O.M., Jakes, R., Curran, M.D. and Wallace, A. (1998) Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of alpha-synuclein protein implicated in Parkinson's disease. FEES Lett., 440, 67-70.
166. Hu, H.Y., Li, Q., Cheng, H.C. and Du, H.N. (2001) β-Sheet structure formation of proteins in solid state as revealed by circular dichroism spectroscopy. Biopolymers, 62, 15-21.
167. Perrin, R.J., Woods, WS., Clayton, D.F. and George, J.M. (2001) Exposure to long chain polyunsaturated fatty acids triggers rapid multimerization of synucleins. J. Biol. Chem., 276, 41958-41962.
168. Lotharius, J., Barg, S., Wiekop, P, Lundberg, C., Raymon, H.K. and Brundin, P. (2002) Effect of mutant α-synuclein on dopamine homeostasis in a new human mesencephalic cell line. J. Biol. Chem., 26, 26.
169. Xu, J., Kao, S.Y., Lee, F.J., Song, W., Jin, L.W. and Yankner, B.A. (2002) Dopamine-dependent neurotoxicity of α-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat. Med., 8, 600-606.
170. Lee, F.J., Liu, F., Pristupa, Z.B. and Niznik, H.B. (2001) Direct binding and functional coupling of α-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. FASEB J., 15, 916-926.
171. Perez, R.G., Waymire, J.C., Lin, E., Liu, J.J., Guo, F. and Zigmond, M.J. (2002) A role for α-synuclein in the regulation of dopamine biosynthesis. J. Neurosci., 22, 3090-3099.
172. Ostrerova, N., Petrucelli, L., Farrer, M., Mehta, N., Choi, P, Hardy, J. and Wolozin, B. (1999) α-Synuclein shares physical and functional homology with 14-3-3 proteins. J. Neurosci., 19, 5782-5791.
173. Broadie, K., Rushton, E., Skoulakis, E.M. and Davis, R.L. (1997) Leonardo, a Drosophila 14-3-3 protein involved in learning, regulates presynaptic function. Neuron, 19, 391-402.
174. Martin, H., Rostas, J., Patel, Y. and Aitken, A. (1994) Subcellular localisation of 14-3-3 isoforms in rat brain using specific antibodies. J. Neurochem., 63, 2259-2265.
175. Patel, Y., Martin, H., Howell, S., Jones, D., Robinson, K. and Aitken, A. (1994) Purification of 14-3-3 protein and analysis of isoforms in chicken brain. Biochim. Biophys. Acta, 1222, 405-409.
176. Tzivion, G. and Avruch, J. (2002) 14-3-3 proteins: active cofactors in cellular regulation by serine/threonine phosphorylation. J. Biol. Chem., 277, 3061-3064.
177. Roth, D., Morgan, A., Martin, H., Jones, D., Martens, G.J., Aitken, A. and Burgoyne, R.D. (1994) Characterization of 14-3-3 proteins in adrenal chromaffin cells and demonstration of isoform-specific phospholipid binding. Biochem. J., 301, 305-310.
178. Roth, D., Birkenfeld, J. and Betz, H. (1999) Dominant-negative alleles of 14-3-3 proteins cause defects in actin organization and vesicle targeting in the yeast Saccharomyces cerevisiae. FEBS Lett., 460, 411-416.
179. Ichimura, T., Isobe, T., Okuyama, T., Takahashi, N., Araki, K., Kuwano, R. and Takahashi, Y. (1988) Molecular cloning of cDNA coding for brain-specific 14-3-3 protein, a protein kinase-dependent activator of tyrosine and tryptophan hydroxylases. Proc. Natl Acad. Sci. USA, 85, 7084-7088.